Press2022-12-28T15:23:07-05:00

Press Releases

2906, 2023

Bexion Pharmaceuticals, Inc. to Present at the ESMO World Congress on Gastrointestinal Cancer 2023

COVINGTON, Ky., June 29, 2023– Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will be represented at the ESMO World Congress on Gastrointestinal Cancer 2023 taking place on June 28 – July 1, 2023, in Barcelona, Spain. Presentation Details: Title: BXQ-350: [...]

1404, 2023

Bexion Pharmaceuticals, Inc. to Present at the 2023 American Association for Cancer Research (AACR) Annual Meeting and the International Ceramide Conference (ICC)

FOR IMMEDIATE RELEASE [Covington, KY--- April 18, 2023] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that the Company will be represented at two upcoming prestigious scientific conferences: American Association for Cancer Research Annual Meeting (AACR) April 14-19, 2023 Orlando, Florida Bexion [...]

1104, 2023

Bexion Pharmaceuticals, Inc. to Present at the 22nd Annual Needham Virtual Healthcare Conference

FOR IMMEDIATE RELEASE [Covington, KY--- April 11, 2023] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that Bexion Pharmaceuticals will be presenting at the Needham Healthcare Conference. The conference will be held virtually from April 17-20, 2023. Scott Shively, Bexion’s CEO and President, [...]

2302, 2023

Bexion Pharmaceuticals, Inc. Announces Publication of Pediatric Phase 1 (KOURAGE) Results

Study achieved planned maximum dose of BXQ-350 with strong safety profile FOR IMMEDIATE RELEASE Covington, KY, February 23, 2022 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today results from their clinical trial entitled, “An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent [...]

1101, 2023

Bexion Pharmaceuticals, Inc. Announces First Patient Dosed with BXQ-350 in the ASIST Clinical Study

Study Aims to Assess Safety and Efficacy of BXQ-350 in Combination with Standard of Care for mCRC FOR IMMEDIATE RELEASE Covington, KY, January 10, 2022 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today that the first adult patient has been dosed in the Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy [...]

1810, 2022

Bexion Pharmaceuticals, Inc. Announces First Patient Dosed with BXQ-350 in the RETRO Clinical Study

Study Aims to Assess Potential for BXQ-350 to Reduce the Intensity and/or Duration of Chemotherapy-Induced Peripheral Neuropathy (CIPN), a Prevalent Limitation of Existing Chemotherapies FOR IMMEDIATE RELEASE Covington, KY, October 18, 2022 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today that the first adult patient has been dosed in the Pilot Proof of [...]

Go to Top